SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML
- First ASXL1 Pediatric Acute Myeloid Leukemia (AML) Patient Dosed at MD Anderson Cancer Center: Program Supported by Rare Pediatric Disease Designation (RPDD)
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ('SELLAS'' or the 'Company'), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the first pediatric AML patient has been dosed in the ongoing Phase 2 trial of SLS009 (tambiciclib), a highly selective CDK9 inhibitor, in relapsed/refractory acute myeloid leukemia (r/r AML).
'Building upon our promising Cohort 3 data, we are pleased to dose our first pediatric AML patient as part of the ongoing Phase 2 trial,' said Dragan Cicic, MD, Chief Development Officer of SELLAS. 'This milestone reflects our commitment to addressing critical unmet needs in hematologic disorders as we develop treatments for the most difficult to treat patients, particularly pediatric patients, with very few available options, including multi-hit TP53 mutation, failure of azacitidine and venetoclax, failure of transplant, and almost all available high-intensity chemotherapies. With the Rare Pediatric Disease Designation already in place, we are hopeful that our work will bring meaningful progress and potential regulatory advantages as we continue to advance this important program.'
SELLAS was granted the FDA RPDD for the treatment of pediatric AML in July 2024. If, in the future, a New Drug Application (NDA) for SLS009 for the treatment of pediatric AML is approved by the FDA, SELLAS will be eligible to receive a Priority Review Voucher (PRV) that could be redeemed to receive a priority review for any subsequent marketing application. PRVs may be used by the sponsor or sold to another sponsor for their use and have recently sold for approximately $100 million.
The Phase 2 clinical trial of SLS009 is an open-label, single-arm, multi-center study designed to evaluate the safety, tolerability, and efficacy of SLS009 in combination with venetoclax and azacitidine at two dose levels, 45 and 60 mg. In the 60 mg dose cohort, patients were treated at either a 60 mg dose once per week or a 30 mg dose two times per week. The trial was expanded to include two additional cohorts, one with ASXL1-mutated AML patients and one with patients with myelodysplasia-related molecular abnormalities other than ASXL1. The target response rate at the optimal dose level is 20% with a target median survival of at least 3 months. In addition, the study aims to identify biomarkers for the target patient population and enrichment for further trials. For more information on the study, visit clinicaltrials.gov identifier NCT04588922.
About SELLAS Life Sciences Group, Inc.
SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS' lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has the potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing SLS009 (tambiciclib) - potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared to other CDK9 inhibitors. Data suggests that SLS009 demonstrated a high response rate in AML patients with unfavorable prognostic factors including ASXL1 mutation, commonly associated with poor prognosis in various myeloid diseases. For more information on SELLAS, please visit www.sellaslifesciences.com.
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts are 'forward-looking statements,' including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as 'plan,' 'expect,' 'anticipate,' 'may,' 'might,' 'will,' 'should,' 'project,' 'believe,' 'estimate,' 'predict,' 'potential,' 'intend,' or 'continue' and other words or terms of similar meaning. These statements include, without limitation, statements related to the GPS clinical development program, including the REGAL study and the timing of future milestones related thereto. These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption 'Risk Factors' in SELLAS' Annual Report on Form 10-K filed on March 20, 2025 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS' forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations, or other circumstances that exist after the date as of which the forward-looking statements were made.
Investor Contact
Bruce Mackle
Managing Director
LifeSci Advisors, LLC
SELLAS@lifesciadvisors.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Bull of the Day: Flotek Industries (FTK)
Flotek Industries (FTK) is a Zack Rank #1 (Strong Buy) that delivers sustainable chemistry solutions and real-time data analytics to clients across the energy and industrial sectors. The stock has surged to multi-year highs after a strong earnings report. Investors are starting to notice this relative strength in a sector that has been weak so far in 2025. Flotek Industries, Inc. is a Houston-based technology company that operates through two core segments: Chemistry Technologies (CT) and Data Analytics (DA). Its Chemistry Technologies division formulates and supplies environmentally conscious specialty chemicals designed to improve the efficiency and profitability of oil and gas production. These green chemistries are tailored to support a broad range of energy producers, including those in oil, gas, geothermal, and alternative energy. The Data Analytics segment complements Flotek's chemistry business by providing real-time measurement and insight tools that allow customers to monitor and optimize their operations while reducing emissions and carbon intensity. The company is valued at $450 million and has a Forward PE of 30. The stock has Zacks Style Scores of 'A' in Growth but 'D' in Value. Flotek reported a strong first quarter, delivering earnings of $0.17 per share, or a 183% EPS surprise to the upside. Revenue came in at $55.4 million, a 37% year-over-year increase. Both segments helped the quarter, with chemistry revenue up 36% and data analytics jumping 57%. Gross margin reached 23%, and net income rose 244%. Adjusted EBITDA more than doubled to $7.8 million, marking the fifth consecutive quarter of growth. The company guided full-year 2025 revenue to $200–210 million (vs. $203 million expected) and adjusted EBITDA of $34–39 million. At the midpoint, that implies 128% growth in both metrics, with EBITDA margin expected to expand to 17%, up from 11% in 2024. Flotek Industries, Inc. price-eps-surprise | Flotek Industries, Inc. Quote Flotek continues to scale its data analytics business rapidly, underpinned by its April acquisition of 30 gas monitoring and dual-fuel optimization assets tied to a $160 million multi-year contract. That deal is expected to generate over $20 million in annual operating income and push fixed-fee DAS revenue above $27 million in 2026. The stock surged after the earnings report, moving from the $8 area to $16 is just over a week. There has been about a month of consolidation since, but the stock remains near its recent post-earnings highs. Looking at analyst estimates, there is little movement on the short-term timeframe, but upside when looking down the road. For the current quarter, estimates have been lowered over the last 30 days from $0.11 to $0.10. For next quarter there have been no adjustments. For the current year we see numbers going higher over the last 90 days, moving from $0.43 to $0.53, or 23%. For next year there has been a move higher in estimates in just the last 30 days. Numbers have been taken from $0.58 to $0.67, or 15%. The stock has experienced a big move over the last month, more than doubling from the pre-earnings levels. A decade ago, the stock was at much higher levels, and after being left for dead in 2024 is back on the rise. Looking at the long-term chart, the downward trend is clearly broken. The stock has short-term room to the 2020 highs around $19, but investors would be better off waiting for pullbacks, rather than chasing. Let's look at some moving averages where bulls should be watching for support. 21-day: $14.60 50-day: $10.40 200-day: $8.00 Fibonacci Support levels reside at $11.40(50%) and $10.30 (61.8%). Flotek Industries has emerged as a standout in the energy sector, combining strong earnings momentum with a compelling growth story centered on green chemistry and real-time data analytics. The recent price surge reflects investor enthusiasm, but the technical setup suggests that pullbacks to key support levels may offer better entry points for long-term buyers. As energy markets remain volatile and capital flows shift toward differentiated tech-enabled solutions, Flotek's integrated platform and strategic growth initiatives could help it outperform peers. The stock's strong Zacks Rank, paired with bullish revisions and renewed institutional attention, reinforces the bullish case. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Flotek Industries, Inc. (FTK) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
31 minutes ago
- Yahoo
With Rick Perry's backing and $50 million from the state, Texas set to become a leader in psychedelics research
As Texas sets to crack down on the recreational use of cannabis, state leaders are opting to invest $50 million in another plant with purported medicinal benefits – a psychedelic called ibogaine. For several years, people have silently traveled to clinics in Mexico to take ibogaine. The extract of an ancient African shrub has been used across the Texas border to alleviate addiction and brain trauma. Texas Gov. Greg Abbott is set to sign Senate Bill 2308 on Wednesday, creating a consortium of universities, hospitals, and drug developers to conduct clinical trials on an ibogaine drug, with the hopes of receiving U.S. Food and Drug Administration approval. Lawmakers approved $50 million in taxpayer dollars to support this effort, making Texas the global leader in psychedelic research investment. Since Texas is trying to be the first to develop the drug, the legislation ensures Texas retains control of the research and development process. The goal of this investment is to ensure Texans reap the economic benefits from an ibogaine treatment program, not a pharmaceutical company. The investment entitles Texas to at least 20% of any successful ibogaine drug resulting from the trials, with a quarter of that revenue allocated to a fund for state veterans. After a failed attempt in Kentucky to start a state-funded ibogaine drug, Texas has picked up the effort under the leadership of a familiar statewide figure-turned psychedelics cheerleader — former Gov. Rick Perry. 'None of this is possible without Perry,' said Bryan Hubbard, the former chair of the Kentucky Opioid Abatement Advisory Commission and current executive director of the American Ibogaine Initiative. 'He made it happen in Texas. That is a big deal and catches the attention of the nation.' Ibogaine is an illegal drug that has found itself in a unique position where Republicans champion it. This comes as some of them, led by Lt. Gov. Dan Patrick, have made it a mission this session to ban recreational use of THC, which awaits Abbott's approval. Katharine Neill Harris, a drug policy fellow at Rice University's Baker Institute for Public Policy, said it's easy for Republicans to sign on to ibogaine because the intent of it is to medicinally treat addiction. 'Also, this bill doesn't grant public access to ibogaine, and there's nothing in the bill that could really be construed as soft on drugs,' she said. For that reason seemingly, Patrick has publicly thrown his support toward ibogaine as he fends off critics from the left and right for his hardline views on THC. Patrick did not respond to a request for a comment for this story. Harris said Texas' investment in ibogaine could kickstart a trend across states to invest in drug research to address addiction, as private funds have become inconsistent. 'In 2024, the FDA rejected a proposal to approve MDMA-assisted therapy for PTSD. MDMA-assisted therapy for PTSD is one of the more studied alternative psychedelic treatment protocols, and the FDA rejection was a huge blow to private industry, likely leading some to rethink investment in this area,' she said. It was early 2022, and the only thing former Army Ranger Chase Rowan could think about was killing himself. Sixteen years prior, his parachute failed to fully deploy during a nighttime training exercise as his body careened toward the ground at 60 miles per hour. To cope through the pain from the severe brain injury that resulted, the Lubbock resident turned to opioids which morphed into a fentanyl addiction that eventually dissolved his family. 'I was stuck alone. I had no money and no vehicle, just white knuckling sobriety,' Rowan said. When Rowan got to Mexico to test out a novel drug called ibogaine in August of 2022, he wasn't scared, but determined to heal. Upon taking the ibogaine pill, Rowan started seeing images — one of a devil with wings and another of roads leading to childhood memories. The psychedelic journey on his first night opened his eyes to past trauma and the pain he caused to those around him, like a movie. He woke up the next day feeling the happiest he had been in 20 years. 'It felt like a weight was lifted off of me,' he said. 'I got that stuff out of me.' What Rowan was dealing with is a particular high that comes from ibogaine that is often referred to as a 'spiritual awakening' or a greater sense of self. Stanford Medicine conducted a study in 2024 that found 'ibogaine, when combined with magnesium to protect the heart, safely and effectively reduces PTSD, anxiety and depression and improves functioning in veterans with' traumatic brain injury. Hubbard sees no threat of ibogaine becoming recreationally used or abused since it does not provide an enjoyable high and leaves the user in a state of temporary paralysis. Because of this, most never go back for another dose. 'There is no street economy for this drug,' Hubbard said. Ibogaine also comes with potential dangers. Harris calls it one of the 'more complicated psychedelics to administer' because it brings risks of cardiac issues and sudden death. The risks make it more expensive to study and to provide as a treatment, drawing out the years that ibogaine becomes more widely available, Harris said. 'If the FDA were to approve ibogaine for opioid use disorders or other disorders…the treatment could be quite costly,' Harris said. Since leaving his two-year stint as U.S. Energy Secretary during the first Trump administration, Perry has thrown the weight of his reputation behind psychedelics, becoming one of the most high-profile advocates of its research nationally. But the journey to this point started when he still occupied the Governor's Mansion in Austin. 'It's the question I hear the most,' Perry said with a laugh. 'What is a right-wing anti-drug governor doing associated with psychedelics?' In 2006, Perry became close with Navy SEAL veteran Marcus Luttrell who struggled from a brain injury, PTSD and addiction, without access to effective treatments. He recalls Luttrell sleeping with the TV and lights on, trying to comfort his battered mind. When Luttrell told him he was planning to go to Mexico with several other veterans to try ibogaine, Perry was skeptical. 'I remember the first time he told me, and I looked at him the same way a dog does when they hear a funny noise. I remember telling him to be careful with that because I still had my beliefs on drugs at the time, but at the same time, people that I trusted were going to Mexico for this, I had to listen,' Perry said. The data was indisputable to Perry. He unequivocally believes ibogaine takes away addiction and he is ready to tell anyone who will ask him about it. He has since gone on to the Joe Rogan podcast to wax poetic about the drug and other psychedelic treatments. He is a scheduled speaker for a psychedelic conference in Denver. He is also planning to reach out to officials in Israel and Ukraine to initiate ibogaine treatment programs there. 'I have always been open to new knowledge. The same thing with criminal justice reform and in-state tuition, as a Republican, I have my beliefs, but I am willing to change them once looking at the data and science,' Perry said. Hubbard cautioned that ibogaine is not a drug to be taken without medical supervision and Texas is probably at least six years away from seeing any movement on FDA approval for clinical trials. However, he is hopeful that the drug qualifies for a Breakthrough Therapy designation, a pathway that accelerates the regulatory review of drugs showing early promise in treating severe conditions. As of June 30, 2024, the FDA has only granted 587 designations out of the 1,516 requested since 2012. Hubbard believes the current presidential administration will see the momentum in Texas and help expedite the process with the FDA. 'If Texas can create a treatment plan for ibogaine, it might be the most significant achievement in modern medicine for nearly a century,' said Hubbard. Disclosure: Rice University and Rice University's Baker Institute for Public Policy have been financial supporters of The Texas Tribune, a nonprofit, nonpartisan news organization that is funded in part by donations from members, foundations and corporate sponsors. Financial supporters play no role in the Tribune's journalism. Find a complete list of them here. Big news: 20 more speakers join the TribFest lineup! New additions include Margaret Spellings, former U.S. secretary of education and CEO of the Bipartisan Policy Center; Michael Curry, former presiding bishop and primate of The Episcopal Church; Beto O'Rourke, former U.S. Representative, D-El Paso; Joe Lonsdale, entrepreneur, founder and managing partner at 8VC; and Katie Phang, journalist and trial lawyer. Get tickets. TribFest 2025 is presented by JPMorganChase.
Yahoo
31 minutes ago
- Yahoo
Vivos Therapeutics Completes Acquisition of The Sleep Center of Nevada
LITTLETON, Colo., June 11, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ('Vivos' or the 'Company') (NASDAQ: VVOS), a leader in delivering and promoting sleep wellness and health through its proprietary, non-invasive treatments for obstructive sleep apnea (OSA), today announced the closing of its acquisition of the operating assets of The Sleep Center of Nevada (SCN), the largest operator of medical sleep centers in Nevada. The SCN transaction represents Vivos' first major acquisition of a sleep testing center and associated medical sleep practice. It is expected to add higher margin revenue to Vivos' operations from both sleep disorder diagnosis and consulting, and from expected sales of Vivos' portfolio of patented, FDA-cleared OSA appliance treatments to SCN's patients. Strategic Business Model Pivot Complete; Anticipated Benefits to Vivos from the Acquisition The closing of this transaction marks the completion of the pivot of Vivos' sales, marketing, and distribution model, which began last year. Vivos has shifted its model from one focused on dental providers who subscribe to be a part of the Vivos network and purchase its appliances, to one where Vivos collaborates with or acquires medical sleep practices, which will allow Vivos to capture OSA diagnostic and consultation revenue immediately and give Vivos the potential to provide Vivos' OSA treatment directly to many more patients. Vivos is currently pursuing additional collaborations or acquisitions to expand its business further during 2025 and beyond. SCN sees approximately 3,000 new patients per month for testing, consultation, and treatment of conditions like OSA, insomnia, and restless leg syndrome, and has generated annual net revenues in the high seven-figure range in recent years. Under the leadership of board certified sleep specialists Dr. Prabhu Rachakonda and his daughter Dr. Tara Rachakonda, each of whom are joining Vivos and will continue active management of their practice, SCN has grown to seven locations with nearly 50 beds currently available for overnight polysomnogram (PSG) testing and consultation, making SCN the largest sleep testing center in Nevada. Approximately 90% of SCN patients test positive for OSA or other sleep disorders. However, an overwhelming percentage of these SCN patients are currently referred out for less effective legacy OSA treatments like CPAP, surgery, or other oral devices. Since 2019, SCN's physicians and nurse practitioners have tested and treated over 200,000 sleep disorder patients, many of whom have stopped using CPAP or are looking for OSA treatment alternatives. This creates a very promising opportunity for SCN patients to be candidates for Vivos' diagnostic and appliance treatment therapies, an opportunity which is at the heart of Vivos' new business model and core value proposition. Effective immediately, Vivos will manage and capture both diagnostic and consulting revenues, representing new, higher-margin revenue streams for Vivos, as well as potential Vivos appliance sales revenue from SCN. In anticipation of the SCN acquisition closing and to allow for immediate patient treatment post-closing, Vivos worked with SCN to properly equip, hire staff, and provide training at two of SCN's seven locations, including SCN's largest location. Over the next 12 to 18 months, additional SCN locations will be similarly built out to offer Vivos treatment. As a result, Vivos expects its diagnostic and appliance treatment revenues from the SCN acquisition to ramp over that period as additional SCN locations are fully integrated and more of SCN's existing and new patient base get evaluated and treated. Vivos will manage SCN under customary agreements designed to comply with applicable corporate practice of medicine laws. Acquisition Financing At the closing, Vivos paid $6 million in cash and $1.5 million in Vivos common stock to SCN. An additional $1.5 million in Vivos common stock may be earned in the future if SCN achieves an agreed to financial milestone. Vivos financed the cash closing payment to SCN by obtaining a senior, non-convertible, secured term loan from Streeterville Capital LLC in the principal amount of $8,225,000. This amount includes a $675,000 original issuance discount and other expense items for gross loan proceeds to Vivos of $7,500,000. This loan is secured by Vivos' interest in the SCN practice, bears interest at 9 percent per year, matures in 18 months, with partial loan amortization payments commencing in six months, and a monitoring fee to be added to the loan balance if the loan is not repaid in 120 days. In addition, an affiliate of New Seneca Partners, an existing significant private equity investor in Vivos, made an additional $3,755,000 private placement investment in Vivos as part of the transaction. This investment consisted of 828,000 shares of Vivos common stock, a pre-funded warrant to purchase 725,258 shares of common stock, and a five-year warrant to purchase 2,329,886 shares of common stock at an exercise price of $2.23 per share. The shares of common stock, pre-funded warrant, and associated warrant were purchased at $2.42 per share and warrant, the price of which was structured to be 'at the market' for Nasdaq Stock Market purposes. The loan and equity investments, totaling over $11 million in gross proceeds to Vivos, will provide important cash resources to Vivos as it looks to fully integrate SCN into its operations and provide working capital as Vivos pursues additional transactions in line with its business model. 'We are extremely pleased to get this first acquisition under our belt and are excited to reap the benefits of our business model pivot,' stated Kirk Huntsman, Vivos' Chairman and CEO. 'We started booking SCN patients over the past few weeks in anticipation of closing, and we are already fully booked out for the entire month of June and into late July with OSA patients seeking alternatives to CPAP and other less effective legacy OSA treatments. The high level of enthusiasm for Vivos began with our new team members, Dr. Prabhu Rachakonda and Dr. Tara Rachakonda, both accomplished board-certified sleep specialists, who were themselves among the first patients to be treated. With that kind of leadership, it's easy to understand our enthusiasm for this acquisition and the prospects for similar transactions in the future as we seek to ramp our revenue significantly.' 'We are truly excited to be a part of the Vivos team and bring this revolutionary, patented, and FDA-cleared treatment to our practice,' said SCN's founder, Dr. Prabhu Rachakonda. 'Because of Vivos, we finally have what we believe is a real solution for OSA, a worldwide debilitating medical condition. My daughter and I believe in this so strongly that we are undergoing Vivos treatment ourselves. No one should have to endure a lifetime of nightly CPAP when there is a highly effective, patient-friendly treatment available that offers the prospect of complete resolution of symptoms. We look forward to working with Vivos on scaling our business and offering the exciting portfolio of Vivos treatments to our patients.' Michael Skaff, Managing Director of New Seneca Partners, stated, 'We have been in lockstep with Vivos management as they've executed on this strategic pivot toward affiliations with and acquisitions of sleep medicine and sleep testing centers. Our follow-on equity investment alongside the new senior debt lender reflects our significant enthusiasm and commitment to what Vivos is doing and the potential within their new model. We fully expect the benefits to Vivos will be significant and will scale as this transaction matures and higher volumes of patients get treated. With the SCN acquisition, Vivos now has direct access to patients, which sleep testing centers such as SCN have in abundance. We believe SCN's existing revenues will be meaningfully augmented in several important ways, all of which we expect to significantly reduce Vivos' cash burn and move Vivos towards cash flow positivity.' Additional details regarding this transaction will be disclosed by Vivos in a Current Report on Form 8-K to be filed with the U.S. Securities and Exchange Commission. About Vivos Therapeutics Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods that promote sleep wellness and health for patients suffering from breathing and sleep issues such as obstructive sleep apnea (OSA) and snoring in adults. Vivos' Complete Airway Repositioning and/or Expansion (CARE) devices are the only oral appliances cleared by the U.S. Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA (including severe OSA) and moderate-to-severe OSA in children ages 6 to 17 within the FDA cleared usage for such devices. Obstructive sleep apnea (OSA) affects over 1 billion people worldwide, yet 90% remain undiagnosed and unaware of their condition. This chronic disorder is not just a sleep issue—it's closely linked to many serious chronic health conditions. While the medical community has made strides in treating sleep disorders, breathing and sleep health remain areas that are still not fully understood. As a result, solutions are often mechanistic and fail to address the root causes of OSA. Vivos Therapeutics, founded in 2016 and based in Littleton, CO, is changing this. Through innovative technology, education, and collaborations with or acquisitions of functional medicine doctors, and sleep specialists, Vivos is empowering healthcare providers to more thoroughly address the complex needs of patients suffering with OSA. Vivos' portfolio of cutting-edge oral appliances offer a proprietary, clinically effective OSA solution that is nonsurgical, noninvasive, and nonpharmaceutical, providing hope to allow patients to . For more information, visit Cautionary Note Regarding Forward-Looking Statements This press release, including statements of the Company's management and other parties made herein, contain 'forward-looking statements' (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as 'may', 'would', 'should', 'expects', 'projects,' 'potential,' 'intends', 'plans', 'believes', 'anticipates', 'hopes', 'estimates', 'goal'. 'aim' and variations of such words and similar expressions are intended to identify forward-looking statements. In this press release, forward-looking statements include, without limitation, those relating to (i) the timing for Vivos' full integration of the SCN business and the actual future impact of the SCN acquisition on Vivos' future revenues and results of operations and (ii) the anticipated benefits and potential expansion of Vivos' marketing and distribution model as described herein, including the potential for Vivos to engaging in similar transactions in the future. These statements involve significant known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos' control. Readers are cautioned that actual results may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that Vivos may be unable to service and ultimately repay its new senior debt facility, (ii) the risk that Vivos may be unable to successfully integrate SCN's business into its own or otherwise implement sales, marketing and other strategies (including collaboration or acquisition transactions) that increase revenues and cash flows, (iii) the risk that some patients may not achieve the desired results from using Vivos' products, (iv) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea diagnosis and treatment sector; (v) the risk that Vivos may be unable to secure additional financing beyond that which is needed to acquire and integrate SCN on reasonable terms when needed, if at all, or maintain its Nasdaq listing, (vi) market and other conditions that could impact Vivos' business or ability to obtain financing, and (vii) other risk factors described in Vivos' filings with the Securities and Exchange Commission ('SEC'). Vivos' filings can be obtained free of charge on the SEC's website at Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos' expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based. Investor and Media Inquiries: R, Kirk Huntsman, CEO, Vivos Therapeutics, investors@ (720) 399-9322Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
